340bemployed.org

Your Free Source for 340B News and Commentary

  • Home
  • About Us
  • Employers
  • Job Seekers
  • Advertise
  • 340B Health

OPA Begins Rule-making for 340B Dispute Resolution and Manufacturer Fines for Overcharges

Comments on both are due by Nov. 19.
 

Print Article

September 20, 2010—The Health Resources and Services Administration (HRSA) formally invited 340B stakeholders today to begin providing their best advice on forthcoming regulations to create an administrative dispute resolution process for the outpatient drug discount program and for fines against drug companies that deliberately overcharge providers for drugs.

The announcements, known as advance notices of proposed rulemaking, were published in the Sept. 20 Federal Register. Cmdr. Krista Pedley, who took over as director of HRSA’s Office of Pharmacy Affairs (OPA) this summer, broke the news of their release in Chicago late last week during a major drug industry annual conference on Medicaid rebates, 340B and other government drug pricing programs.

Implementation Hinges on Funding

Pedley said that while HRSA and OPA will promulgate rules to create the dispute resolution and civil monetary penalty processes, it will not actually implement either one until OPA secures more funding from the government. She noted that her office now spends about $15 million per year, or about three times the amount of the $5.2 million appropriation it would get under President Obama’s budget request for the fiscal year that starts Oct. 1.

The Department of Health and Human Services (HHS) currently covers OPA’s over-budget spending by shifting money to it from other accounts. If Congress fails to pass a regular appropriations bill for HHS before the new fiscal year begins, OPA’s budget will likely remain at its current $2.2 million level, and it is anyone’s guess whether the funds will be there to allow the office to get the two new program integrity initiatives up and running.

First-ever 340B Regulations

The pair of regulations, Pedley noted, will be the first in the 340B program’s history. The national health care reform law enacted in March established both program integrity initiatives and gave HHS a 180-day deadline to begin rule-making for them.

Pedley candidly acknowledged during the Chicago gathering that OPA is in uncharted waters when it comes to drafting formal regulations, as compared with less stringent guidance, and strongly urged the industry representatives in attendance to submit comments by the Nov. 19 deadline.

Focus Areas

With respect to the dispute resolution process, HRSA and OPA are “expressly” seeking input on:

  • administrative procedures,
  • existing models,
  • threshold requirements,
  • hearings,
  • decision-making official or body,
  • appropriate appeals procedures,
  • deadlines,
  • discovery procedures,
  • manufacturer audits of 340B covered entities,
  • consolidation of manufacturer claims against covered entities,
  • consolidation of covered entity claims against manufacturers,
  • claims by third parties representing covered entities, and
  • integration of dispute resolutions with other Affordable Care Act (ACA) provisions.

With respect to civil monetary penalties for manufacturer overcharging, HRSA and OPA are seeking comments specifically on:

  • existing models,
  • threshold determinations,
  • administrative process elements,
  • hearings,
  • appeals processes,
  • definitions,
  • penalty computation,
  • penalty payment, and
  • integration with other ACA provisions.

The Monitor will be taking a closer look in coming days at what specific sorts of advice HRSA and OPA are seeking in these issue areas.

Comments in response to the notice on the dispute resolution process should be marked “Comments on Administrative Dispute Resolution Process” and sent to Dorcas Ann Taylor, Public Health Analyst, Office of Pharmacy Affairs (OPA), Health Systems Bureau (HSB), Health Resources and Services Administration (HRSA), 5600 Fishers Lane, Parklawn Building, Room 10C-03, Rockville, MD 20857. Comments may also be emailed to: opadrp@hrsa.gov.

Comments in response to the notice on civil monetary penalties should be marked “Comments on the Civil Monetary Penalties” and sent to Bradford R. Lang, Public Health Analyst, Office of Pharmacy Affairs (OPA), Health Systems Bureau (HSB), Health Resources and Services Administration (HRSA), 5600 Fishers Lane, Parklawn Building, Room 10C-03, Rockville, MD 20857. OPA is also accepting comments on this notice via email at: opacmp@hrsa.gov.

Follow us on X

340B Health Follow

340B Health is the leading advocate & resource for hospitals that serve their communities by participating in the 340B drug pricing program. #Protect340B

340BHealth
340bhealth 340B Health @340bhealth ·
16 Feb

There’s a reason why you may have been hearing some controversial things about #340B lately. These misinformation campaigns go way back and have trails leading to Big Pharma. Learn why pharma-funded groups are invested in derailing a federal program that doesn’t cost the…

Reply on Twitter 1890990490486726953 Retweet on Twitter 1890990490486726953 1 Like on Twitter 1890990490486726953 3 Twitter 1890990490486726953
340bhealth 340B Health @340bhealth ·
15 Feb

It would cost just one safety-net hospital $24 million more each year to pay full price for two @JNJNews drugs upfront and wait for drugmaker rebates that might never come.

Then consider the crippling financial harm that would occur if you were to expand those costs to purchase…

Reply on Twitter 1890756196560482421 Retweet on Twitter 1890756196560482421 1 Like on Twitter 1890756196560482421 1 Twitter 1890756196560482421
340bhealth 340B Health @340bhealth ·
14 Feb

Show the team of experts here at #340B Health some love this Valentine’s Day by streaming our “listener mailbag” episode of #340BInsight: http://bit.ly/3YWHlJ4. Then learn more in just over a week at the @340BCoalition Winter Conference in San Diego!

Reply on Twitter 1890392047640527294 Retweet on Twitter 1890392047640527294 Like on Twitter 1890392047640527294 Twitter 1890392047640527294
Load More

RSS 340B Informed

  • An In-Depth Look at Total 340B Purchases
  • Ideas for 340B Changes Could Lead to Legislation
  • Help From 340B After a Rare Diagnosis and an Unaffordable Bill

Copyright © 2025 · 340B Health